Targeting of solid tumors and blood malignancies by antibody-based therapies - EGFR-pathway as an example
Number of Authors: 5
2006 (English)In: Central European Journal of Biology, ISSN 1895-104X, E-ISSN 1644-3632, Vol. 1, no 2, 167-182 p.Article, review/survey (Refereed) Published
A well-coordinated interaction between extracellular signals and intracellular response forms the basis of life within multicellular organisms, with growth factors playing a crucial role in these interactions. Discoveries in recent years have shown that components of the Epidermal Growth Factor (EGF) signaling system have frequently been used by cancer cells to autonomously provide survival and proliferation signals. The main focus of this review is the ErbB epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases including ErbB1/EGFR, ErbB2/HER2/neu, ErbB3/HER3, and ErbB4/HER4 as therapeutic targets. Since the ErbB receptor family regulates cell proliferation through the Ras-mitogen-activated protein kinase (RAS/MAPK) pathway, and cell survival and transformation through the phosphatidylinositol 3-kinase (PI3K/AKT) pathway, pharmacological targeting of these pathways is also discussed. We will also address the clinical studies that have been conducted to evaluate antibody-based therapies mostly on solid tumors and hematologic malignancies. (c) Versita Warsaw and Springer-Verlag Berlin Heidelberg. All rights reserved.
Place, publisher, year, edition, pages
2006. Vol. 1, no 2, 167-182 p.
Pharmacology and Toxicology
IdentifiersURN: urn:nbn:se:liu:diva-121973DOI: 10.2478/s11535-006-0014-6ISI: 000246983000001OAI: oai:DiVA.org:liu-121973DiVA: diva2:860788